Assembled from the company's filings and exchange data as of today. Download PDF renders this page on the server; the narrative sections arrive with the Nexa composer.
Dossier · ANG Lifesciences India Limited · 30 October 2026Page 1 of 3
Company Dossier
MarketPing Research · factual · no rating expressed
ANG Lifesciences India Limited
BSE: 540694
BSE: 540694
Healthcare › Healthcare › Pharmaceuticals & Biotechnology › Pharmaceuticals
ANG Lifesciences India Limited
StateQ4 FY26 filed
Last close · 30 Oct 2026₹33.00
Market cap₹0.0k cr
TTM P/E · P/B · EV/EBITDA3.9 · 0.81 · 96.0
ANG Lifesciences India Limited is a Pharmaceuticals & Biotechnology company. The annual-report business brief for this company has not been generated yet; the numbers below are as filed.
What a broker report prints here — the analyst's thesis. This dossier prints the filed record instead; the narrative read of the latest results, the guidance ledger and the earnings-call summary are the composer's sections (INSTITUTIONAL-PLAN.md M3) and are not yet produced.
Exhibit 1: Financial summary, FY22–FY26 (all audited; no estimate years)
| ₹ crore · consolidated | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Revenue | 354 | 220 | 146 | 93 | 93 |
| EBITDA (ex other income) | 67 | 14 | 8 | (2) | 1 |
| margin % | 19.0 | 6.4 | 5.4 | (2.4) | 0.8 |
| Owners' profit | 0 | 0 | 0 | 0 | 0 |
| EPS, as reported (₹) | 39.09 | 0.36 | (7.61) | 9.42 | 8.43 |
| ROE % · ROCE % | 48.1 · 50.0 | (0.3) · 12.4 | (13.3) · 0.2 | (19.4) · (8.1) | (21.0) · (8.5) |
| Debt / equity (x) | 0.92 | 0.81 | 0.91 | 1.26 | 1.47 |
| Cash from operations | 25 | 26 | (9) | (0) | 11 |
| Capex | (41) | (10) | (6) | (4) | (0) |
Source: SEBI results XBRL as filed with BSE/NSE; EBITDA excludes other income.
Every figure is a filed number or a ratio over filed numbers · No rating, target or fair value is expressed · Disclosures on the last pagemarketping.in
Dossier · ANG Lifesciences India Limited · 30 October 2026Page 2 of 3
Exhibit 2: Quarterly performance, last 8 quarters
| ₹ crore | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 18 | 33 | 25 | 17 | 25 | 26 | 19 | 24 |
| Profit before tax | (4) | (1) | (6) | (4) | (3) | (3) | (6) | (1) |
| Net profit | (3) | (2) | (5) | (2) | (2) | (3) | (5) | (1) |
| EPS (₹) | (2.35) | (1.53) | (3.98) | 1.56 | 1.52 | 2.24 | 3.60 | 1.07 |
Source: quarterly results as filed; the balance sheet is filed half-yearly and is not repeated here.
Exhibit 3: Segment revenue, FY26
| Segment | Revenue, ₹ crore | Share % |
|---|---|---|
| Pharmaceutical | 49 | 50.6 |
| Printing & Publishers | 3 | 3.0 |
| Pharmaceuticals | 43 | 44.4 |
| Printing & Packaging | 2 | 2.1 |
| Total, before eliminations | 96 | 100.0 |
Source: the filed segment block, four quarters summed.
Exhibit 4: Peers — basic industry group, by market cap
| Company | M.cap ₹ cr | P/E | P/B | EV/EBITDA | ROE % | ROCE % | Rev CAGR 5y % | EBITDA m. % |
|---|---|---|---|---|---|---|---|---|
| SUN PHARMACEUTICAL IND L | 4,31,490 | 35.7 | 5.14 | 23.1 | 13.7 | 17.5 | 11.8 | 32.3 |
| DIVI S LABORATORIES LTD | 2,60,243 | 89.1 | 15.53 | 67.1 | 15.3 | 18.8 | 8.7 | 42.8 |
| TORRENT PHARMACEUTICALS L | 1,57,330 | 74.3 | 8.95 | 39.1 | 12.2 | 8.0 | 11.8 | 33.1 |
| LAURUS LABS LIMITED | 1,27,267 | 116.3 | 23.43 | 70.7 | 16.4 | 17.2 | 7.2 | 32.0 |
| ZYDUS LIFESCIENCES LTD | 1,24,151 | 27.7 | 4.20 | 15.9 | 17.3 | 18.0 | 12.4 | 25.2 |
| DR. REDDY S LABORATORIES | 1,13,351 | 35.1 | 2.96 | 15.1 | 10.9 | 13.0 | 12.1 | 15.0 |
| CIPLA LTD | 1,10,667 | 32.8 | 3.21 | 16.9 | 11.2 | 14.7 | 8.0 | 19.7 |
| MANKIND PHARMA LIMITED | 1,03,931 | 50.9 | 6.28 | 28.6 | 11.7 | 10.8 | — | 27.3 |
Source: exchange data and filed statements via the screener; multiples at current prices.
Exhibit 5: Where the company sits in its group
| Metric | Company | Group median | Rank | Better than |
|---|---|---|---|---|
| P/E (TTM) | 4.0 | 29.7 | 5 of 158 | 98% |
| P/B | 0.8 | 3.0 | 16 of 163 | 91% |
| ROCE | (21.7) | 10.8 | 171 of 183 | 7% |
| ROE | (21.0) | 9.8 | 159 of 166 | 4% |
| Debt / Equity | 1.5 | 0.2 | 159 of 166 | 4% |
| EBITDA margin | 12.1 | 17.5 | 107 of 165 | 35% |
| Revenue growth | 39.7 | 16.3 | 27 of 161 | 84% |
| Profit growth | 32.9 | 30.9 | 77 of 158 | 52% |
| Market cap | 44 | 801 | 150 of 181 | 17% |
Source: MarketPing peer ranks; a rank is a measurement, not a view.
Every figure is a filed number or a ratio over filed numbers · No rating, target or fair value is expressed · Disclosures on the last pagemarketping.in
Dossier · ANG Lifesciences India Limited · 30 October 2026Page 3 of 3
Exhibit 6: Filings of the last 90 days, with the measured price reaction
| Date · filing | Category | Importance | Next day % | 5-day % |
|---|---|---|---|---|
| 16 Oct 2026 · RTA compliance certificate filed under SEBI Reg 74(5) for Sep 2026 quarter | compliance | minimal | — | — |
| 1 Oct 2026 · 20th AGM voting results: all 5 resolutions passed | compliance | minimal | — | — |
| 30 Sept 2026 · Mrs. Chetna re-appointed as Independent Director for 5-year term | management changes | medium | — | — |
| 30 Sept 2026 · ANG Lifesciences 20th AGM held on Sept 30, 2026 | board shareholder meetings | low | — | — |
| 23 Sept 2026 · Trading window closed from Oct 1 ahead of Q2 FY26 results | compliance | minimal | — | — |
| 7 Sept 2026 · ANG Lifesciences submits Annual Report for FY 2025-26; 20th AGM on Sept 30 | results | medium | — | — |
| 7 Sept 2026 · ANG Lifesciences 20th AGM Notice - September 30, 2026 via VC | board shareholder meetings | low | — | — |
| 7 Sept 2026 · Book Closure for 20th AGM from 24 Sep to 30 Sep 2026 | board shareholder meetings | low | — | — |
| 7 Sept 2026 · 20th AGM scheduled for 30 September 2026 via video conference | board shareholder meetings | low | — | — |
| 7 Sept 2026 · ANG Lifesciences board fixes AGM date, re-appoints independent director | management changes | low | — | — |
Source: exchange announcements; each reaction is measured from the close before the filing. Next day = the close one session after the reaction day (the first session that could trade the filing).
How to read this document
| Where a broker report shows | This document shows | Why |
|---|---|---|
| A rating (BUY / ADD / REDUCE / SELL) | A state: the latest filed quarter and the measured reactions | an event is a fact; a rating is an opinion that requires SEBI RA registration |
| A target price and upside | The current price and the multiples against the group | a target is a forecast; a multiple is a measurement |
| Estimate years marked E | More audited years; no estimates | MarketPing publishes no forecasts — your own model lives on the Models page |
Sources, method and disclosures
This document is a statistical summary of publicly filed information and market data, prepared by software from primary sources: SEBI results XBRL filed with BSE and NSE, LODR disclosures, shareholding patterns, exchange price data. It contains no research recommendation, no price target and no opinion on the merits of any security, and is not a research report within the meaning of the SEBI (Research Analysts) Regulations, 2014, Regulation 2(1)(w)(vii). Financial statements are as filed (consolidated where the company files consolidated results). Ratios are computed over filed lines. Where a figure is unavailable the table shows a dash rather than an estimate. The business brief is written by MarketPing's reader from the annual report and checked against it; no figure in a table was generated by a model. Nothing here constitutes investment advice, an offer or a solicitation; readers should consult a SEBI-registered adviser before acting. MarketPing is not a SEBI-registered intermediary.
Every figure is a filed number or a ratio over filed numbers · No rating, target or fair value is expressed · Disclosures on the last pagemarketping.in